真实世界研究:抗抑郁药与抗精神病药及其联合方案维持治疗精神病性抑郁的疗效
该研究基于芬兰和瑞典全国队列,采用个体内设计分析精神病性抑郁患者维持治疗中特定药物与精神科住院风险的关系。结果显示,安非他酮、沃替西汀、文拉法辛、任何长效针剂抗精神病药、氯氮平及少数特定组合与复发风险降低相关,而苯二氮䓬类与米氮平与风险升高相关。
要点
- 安非他酮、沃替西汀、文拉法辛单药与精神病性抑郁复发住院风险降低相关。
- 任何长效针剂抗精神病药和氯氮平均与复发风险降低相关。
- 阿米替林-奥氮平、舍曲林-喹硫平、文拉法辛-喹硫平组合与复发风险降低相关。
核心结论
- 在精神病性抑郁维持治疗中,安非他酮、沃替西汀、文拉法辛、任何长效针剂抗精神病药、氯氮平及少数特定抗抑郁药-抗精神病药组合与复发风险降低相关。
研究设计与样本
- 基于芬兰(2000-2018年)和瑞典(2006-2021年)全国住院、专科门诊、病假和残疾养老金登记,纳入16-65岁首次诊断精神病性抑郁者,采用个体内设计(自身对照)和分层Cox模型分析,两国队列分别分析后以固定效应荟萃分析合并。
主要发现
- 芬兰队列纳入19,330人(平均年龄39.8±14.7岁,57.9%女性),瑞典队列纳入13,684人(平均年龄41.3±14.0岁,53.5%女性)。
- 与不使用抗抑郁药相比,布普品(aHR=0.73,95% CI:0.63-0.85)、沃替西汀(aHR=0.78,95% CI:0.63-0.96)和文拉法辛(aHR=0.92,95% CI:0.86-0.98)与复发风险降低相关。
- 与不使用抗精神病药相比,任何长效针剂(aHR=0.60,95% CI:0.45-0.80)和氯氮平(aHR=0.72,95% CI:0.57-0.91)与复发风险降低相关。
- 单药治疗中,仅沃替西汀(aHR=0.67,95% CI:0.47-0.95)和布普品(aHR=0.71,95% CI:0.56-0.89)与同时不使用抗抑郁药和抗精神病药相比,复发风险显著降低。
- 探索性分析中,与不使用抗抑郁药和抗精神病药相比,阿米替林-奥氮平(aHR=0.45,95% CI:0.28-0.71)、舍曲林-喹硫平(aHR=0.79,95% CI:0.67-0.93)和文拉法辛-喹硫平(aHR=0.82,95% CI:0.73-0.91)与复发风险降低相关;苯二氮䓬类及相关药物(aHR=1.29,95% CI:1.24-1.34)和米氮平(aHR=1.17,95% CI:1.07-1.29)与复发风险升高相关。
关键数值与推荐
- 与不使用相应药物相比,布普品、沃替西汀、文拉法辛、任何长效针剂、氯氮平及阿米替林-奥氮平、舍曲林-喹硫平、文拉法辛-喹硫平组合的调整风险比均小于1且95%置信区间不包含1。
- 米氮平和苯二氮䓬类及相关药物的调整风险比大于1且95%置信区间不包含1。
临床怎么用
- 在精神病性抑郁维持治疗中,可优先考虑与复发风险降低相关的药物,如布普品、沃替西汀、文拉法辛、长效针剂抗精神病药、氯氮平及特定组合。
- 应警惕米氮平和苯二氮䓬类及相关药物可能与复发风险升高相关。
局限性
- 研究为观察性设计,个体内分析虽控制时间不变混杂因素,但仍可能存在时间依赖混杂。
- 探索性分析结果需进一步验证,不能直接推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychotic depression (PD) is a severe mental disorder leading to functional disability and high risk of suicide, but very little is known about the comparative effectiveness of medications used in its maintenance treatment. The objective of this study was to investigate the comparative effectiveness of specific antipsychotics and antidepressants, and their combinations, on the risk of psychiatric hospitalization among persons with PD in routine care. Persons aged 16-65 years with a first-time diagnosis of PD were identified from Finnish (years 2000-2018) and Swedish (years 2006-2021) nationwide registers of inpatient care, specialized outpatient care, sickness absence, and disability pension. The main exposures were specific antipsychotics and antidepressants, and the main outcome measure was psychiatric hospitalization as a marker of severe relapse. The risk of hospitalization associated with periods of use vs. non-use of medications (expressed as adjusted hazard ratio, aHR) was assessed by a within-individual design, using each individual as his/her own control, and analyzed with stratified Cox models. The two national cohorts were first analyzed separately, and then combined using a fixed-effect meta-analysis. The Finnish cohort included 19,330 persons (mean age: 39.8±14.7 years; 57.9% women) and the Swedish cohort 13,684 persons (mean age: 41.3±14.0 years; 53.5% women). Individual antidepressants associated with a decreased risk of relapse vs. non-use of antidepressants were bupropion (aHR=0.73, 95% CI: 0.63-0.85), vortioxetine (aHR=0.78, 95% CI: 0.63-0.96) and venlafaxine (aHR=0.92, 95% CI: 0.86-0.98). Any long-acting injectable antipsychotic (LAI) (aHR=0.60, 95% CI: 0.45-0.80) and clozapine (aHR=0.72, 95% CI: 0.57-0.91) were associated with a decreased risk of relapse vs. non-use of antipsychotics. Among monotherapies, only vortioxetine (aHR=0.67, 95% CI: 0.47-0.95) and bupropion (aHR=0.71, 95% CI: 0.56-0.89) were associated with a significantly decreased risk of relapse vs. non-use of both antidepressants and antipsychotics. In an exploratory analysis of antidepressant-antipsychotic combinations, a decreased relapse risk was found for amitriptyline-olanzapine (aHR=0.45, 95% CI: 0.28-0.71), sertraline-quetiapine (aHR=0.79, 95% CI: 0.67-0.93) and venlafaxine-quetiapine (aHR=0.82, 95% CI: 0.73-0.91) vs. non-use of antidepressants and antipsychotics. Benzodiazepines and related drugs (aHR=1.29, 95% CI: 1.24-1.34) and mirtazapine (aHR=1.17, 95% CI: 1.07-1.29) were associated with an increased risk of relapse. These data indicate that, in the maintenance treatment of PD, bupropion, vortioxetine, venlafaxine, any LAI, clozapine, and only few specific antidepressant-antipsychotic combinations are associated with a decreased risk of relapse. These findings challenge the current recommendation by treatment guidelines to combine an antipsychotic with an antidepressant (without further specification) as standard treatment in PD.
引用
- Taipale H, Lieslehto J, Lähteenvuo M, et al. Real-world effectiveness of antidepressants, antipsychotics and their combinations in the maintenance treatment of psychotic depression. Evidence from within-subject analyses of two nationwide cohorts. World Psychiatry. 2024. PMID: 38727044. doi:10.1002/wps.21205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。